BRCA Mutations Lead to XIAP Overexpression and Sensitise Ovarian Cancer to Inhibitor of Apoptosis (IAP) Family Inhibitors

Overview

Journal Br J Cancer

Specialty Oncology

Date 2022 May 2

PMID 35501389

Authors

Mattia Cremona

Cassandra J Vandenberg

Angela M Farrelly

Stephen F Madden

Clare Morgan

Roshni Kalachand

Jessica N McAlpine

Sinead Toomey

David G Huntsman

Liam Grogan

Oscar Breathnach

Patrick Morris

Mark S Carey

Clare L Scott

Bryan T Hennessy

Affiliations

Soon will be listed here.

Abstract

Background: We tested the hypothesis that inhibitor of apoptosis family (IAP) proteins may be altered in BRCA1-mutated ovarian cancers and that could affect the sensitivity to IAP inhibitors.

Methods: The levels of IAP proteins were evaluated in human cancers and cell lines. Cell lines were used to determine the effects of IAP inhibitors. The in vivo effects of treatments were evaluated in PDX mouse models.

Results: Expression of X-linked inhibitor of apoptosis (XIAP) is increased in BRCA1-mutated cancers and high levels are associated with improved patient outcomes after platinum chemotherapy. XIAP overexpression is mediated by NF-kB activation and is associated with an optimisation of PARP. BRCA1-mutated cell lines are particularly sensitive to IAP inhibitors due to an inhibitory effect on PARP. Both a BRCA1-mutated cell line with acquired resistance to PARP inhibitors and one with restored BRCA1 remain sensitive to IAP inhibitors. Treatment with IAP inhibitors restores the efficacy of PARP inhibition in these cell lines. The IAP inhibitor LCL161 alone and in combination with a PARP inhibitor, exhibited antitumour effects in PDX mouse models of resistant BRCA2 and 1-mutated ovarian cancer, respectively.

Conclusion: A clinical trial may be justified to further investigate the utility of IAP inhibitors.

Citing Articles

Molecular Docking of Lactoferrin with Apoptosis-Related Proteins Insights into Its Anticancer Mechanism.

Angel-Lerma L, Carrillo-Campos J, Sianez-Estrada L, Siqueiros-Cendon T, Leon-Flores D, Espinoza-Sanchez E Int J Mol Sci. 2025; 26(5).

PMID: 40076649 PMC: 11899785. DOI: 10.3390/ijms26052023.

Programmed cell death: molecular mechanisms, biological functions, diseases, and therapeutic targets.

Qian S, Long Y, Tan G, Li X, Xiang B, Tao Y MedComm (2020). 2024; 5(12):e70024.

PMID: 39619229 PMC: 11604731. DOI: 10.1002/mco2.70024.

Prognostic value and therapeutic potential of IAP family in head and neck squamous cell carcinoma.

Yu X, Cao W, Yang X, Yu C, Jiang W, Guo H Aging (Albany NY). 2024; 16(4):3674-3693.

PMID: 38364254 PMC: 10929838. DOI: 10.18632/aging.205551.

Construction and Identification of an NLR-Associated Prognostic Signature Revealing the Heterogeneous Immune Response in Skin Cutaneous Melanoma.

Geng Y, Sun Y, Song H, Miao Q, Wang Y, Qi J Clin Cosmet Investig Dermatol. 2023; 16:1623-1639.

PMID: 37396711 PMC: 10312339. DOI: 10.2147/CCID.S410723.

A signature based on anoikis-related genes for the evaluation of prognosis, immunoinfiltration, mutation, and therapeutic response in ovarian cancer.

Duan Y, Xu X Front Endocrinol (Lausanne). 2023; 14:1193622.

PMID: 37383389 PMC: 10295154. DOI: 10.3389/fendo.2023.1193622.

References

Hennessy B, Timms K, Carey M, Gutin A, Meyer L, Flake 2nd D . Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer. J Clin Oncol. 2010; 28(22):3570-6. PMC: 2917312. DOI: 10.1200/JCO.2009.27.2997. View

Pennington K, Walsh T, Harrell M, Lee M, Pennil C, Rendi M . Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2013; 20(3):764-75. PMC: 3944197. DOI: 10.1158/1078-0432.CCR-13-2287. View

Eoh K, Park J, Park H, Lee S, Han J, Lee J . BRCA1 and BRCA2 mutation predictions using the BRCAPRO and Myriad models in Korean ovarian cancer patients. Gynecol Oncol. 2017; 145(1):137-141. DOI: 10.1016/j.ygyno.2017.01.026. View

Creeden J, Nanavaty N, Einloth K, Gillman C, Stanbery L, Hamouda D . Homologous recombination proficiency in ovarian and breast cancer patients. BMC Cancer. 2021; 21(1):1154. PMC: 8555001. DOI: 10.1186/s12885-021-08863-9. View

Rigakos G, Razis E . BRCAness: finding the Achilles heel in ovarian cancer. Oncologist. 2012; 17(7):956-62. PMC: 3399652. DOI: 10.1634/theoncologist.2012-0028. View

Roy R, Chun J, Powell S . BRCA1 and BRCA2: different roles in a common pathway of genome protection. Nat Rev Cancer. 2011; 12(1):68-78. PMC: 4972490. DOI: 10.1038/nrc3181. View

Fulda S, Vucic D . Targeting IAP proteins for therapeutic intervention in cancer. Nat Rev Drug Discov. 2012; 11(2):109-24. DOI: 10.1038/nrd3627. View

Takahashi R, Deveraux Q, Tamm I, Welsh K, Salvesen G, Reed J . A single BIR domain of XIAP sufficient for inhibiting caspases. J Biol Chem. 1998; 273(14):7787-90. DOI: 10.1074/jbc.273.14.7787. View

Vucic D, Dixit V, Wertz I . Ubiquitylation in apoptosis: a post-translational modification at the edge of life and death. Nat Rev Mol Cell Biol. 2011; 12(7):439-52. DOI: 10.1038/nrm3143. View

10.

Martinez-Ruiz G, Maldonado V, Ceballos-Cancino G, Reyes Grajeda J, Melendez-Zajgla J . Role of Smac/DIABLO in cancer progression. J Exp Clin Cancer Res. 2008; 27:48. PMC: 2566557. DOI: 10.1186/1756-9966-27-48. View

11.

Darding M, Feltham R, Tenev T, Bianchi K, Benetatos C, Silke J . Molecular determinants of Smac mimetic induced degradation of cIAP1 and cIAP2. Cell Death Differ. 2011; 18(8):1376-86. PMC: 3172091. DOI: 10.1038/cdd.2011.10. View

12.

Deng C . BRCA1: cell cycle checkpoint, genetic instability, DNA damage response and cancer evolution. Nucleic Acids Res. 2006; 34(5):1416-26. PMC: 1390683. DOI: 10.1093/nar/gkl010. View

13.

Carey M, Agarwal R, Gilks B, Swenerton K, Kalloger S, Santos J . Functional proteomic analysis of advanced serous ovarian cancer using reverse phase protein array: TGF-beta pathway signaling indicates response to primary chemotherapy. Clin Cancer Res. 2010; 16(10):2852-60. PMC: 2877659. DOI: 10.1158/1078-0432.CCR-09-2502. View

14.

Yang J, Yoshihara K, Tanaka K, Hatae M, Masuzaki H, Itamochi H . Predicting time to ovarian carcinoma recurrence using protein markers. J Clin Invest. 2013; 123(9):3740-50. PMC: 3754259. DOI: 10.1172/JCI68509. View

15.

Stordal B, Timms K, Farrelly A, Gallagher D, Busschots S, Renaud M . BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation. Mol Oncol. 2013; 7(3):567-79. PMC: 4106023. DOI: 10.1016/j.molonc.2012.12.007. View

16.

Varfolomeev E, Blankenship J, Wayson S, Fedorova A, Kayagaki N, Garg P . IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. Cell. 2007; 131(4):669-81. DOI: 10.1016/j.cell.2007.10.030. View

17.

Burke J, Pattoli M, Gregor K, Brassil P, MacMaster J, McIntyre K . BMS-345541 is a highly selective inhibitor of I kappa B kinase that binds at an allosteric site of the enzyme and blocks NF-kappa B-dependent transcription in mice. J Biol Chem. 2002; 278(3):1450-6. DOI: 10.1074/jbc.M209677200. View

18.

Ramakrishnan V, Painuly U, Kimlinger T, Haug J, Rajkumar S, Kumar S . Inhibitor of apoptosis proteins as therapeutic targets in multiple myeloma. Leukemia. 2014; 28(7):1519-28. PMC: 4090267. DOI: 10.1038/leu.2014.2. View

19.

Harte M, Gorski J, Savage K, Purcell J, Barros E, Burn P . NF-κB is a critical mediator of BRCA1-induced chemoresistance. Oncogene. 2013; 33(6):713-723. PMC: 3917825. DOI: 10.1038/onc.2013.10. View

20.

Jacot W, Thezenas S, Senal R, Viglianti C, Laberenne A, Lopez-Crapez E . BRCA1 promoter hypermethylation, 53BP1 protein expression and PARP-1 activity as biomarkers of DNA repair deficit in breast cancer. BMC Cancer. 2013; 13:523. PMC: 4228368. DOI: 10.1186/1471-2407-13-523. View